作者
Øystein Karlstad, Petteri Hovi, Anders Husby, Tommi Härkänen, Randi Marie Selmer, Nicklas Pihlström, Jørgen Vinsløv Hansen, Hanna Nohynek, Nina Gunnes, Anders Sundström, Jan Wohlfahrt, Tuomo A Nieminen, Maria Grünewald, Hanne Løvdal Gulseth, Anders Hviid, Rickard Ljung
发表日期
2022/6/1
期刊
JAMA cardiology
卷号
7
期号
6
页码范围
600-612
出版商
American Medical Association
简介
Importance
Reports of myocarditis after SARS-CoV-2 messenger RNA (mRNA) vaccination have emerged.
Objective
To evaluate the risks of myocarditis and pericarditis following SARS-CoV-2 vaccination by vaccine product, vaccination dose number, sex, and age.
Design, Setting, and Participants
Four cohort studies were conducted according to a common protocol, and the results were combined using meta-analysis. Participants were 23 122 522 residents aged 12 years or older. They were followed up from December 27, 2020, until incident myocarditis or pericarditis, censoring, or study end (October 5, 2021). Data on SARS-CoV-2 vaccinations, hospital diagnoses of myocarditis or pericarditis, and covariates for the participants were obtained from linked nationwide health registers in Denmark, Finland, Norway, and Sweden.
Exposures
The 28-day risk periods after administration date of the first and second doses …
学术搜索中的文章
Ø Karlstad, P Hovi, A Husby, T Härkänen, RM Selmer… - JAMA cardiology, 2022
